Does Rallies show Form 4 insider transactions for CRSP?

Yes. Rallies tracks CRSP insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CRSP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CRSP. It does not provide personalized investment advice.

CRSP (CRISPR Therapeutics AG) Stock Analysis - Insider Trades

CRISPR Therapeutics AG (CRSP) is a publicly traded Healthcare sector company. As of May 20, 2026, CRSP trades at $48.67 with a market cap of $4.68B and a P/E ratio of -7.51. CRSP moved +2.03% today. Year to date, CRSP is -11.97%; over the trailing twelve months it is +23.69%. Its 52-week range spans $30.04 to $78.48. Analyst consensus is buy with an average price target of $75.00. Rallies surfaces CRSP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CRSP stock inside the company?

Recent CRSP insider activity includes KASINGER JAMES R. sold 3.18K, Kulkarni Samarth sold 10.02K, Prasad Raju sold 3.71K, Patel Naimish sold 3.15K, and Prasad Raju sold 5.85K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CRSP Key Metrics

Key financial metrics for CRSP
Metric	Value
Price	$48.67
Market Cap	$4.68B
P/E Ratio	-7.51
EPS	$-6.47
Dividend Yield	0.00%
52-Week High	$78.48
52-Week Low	$30.04
Volume	1.52M
Avg Volume	0
Revenue (TTM)	$3.51M
Net Income	$-581.60M
Gross Margin	0.00%

Recent CRSP Insider Trades

KASINGER JAMES R. sold 3.18K (~$148.85K) on Mar 23, 2026.
Kulkarni Samarth sold 10.02K (~$468.74K) on Mar 23, 2026.
Prasad Raju sold 3.71K (~$173.46K) on Mar 23, 2026.
Patel Naimish sold 3.15K (~$152.02K) on Mar 16, 2026.
Prasad Raju sold 5.85K (~$282.22K) on Mar 16, 2026.

Latest CRSP News

CRISPR Therapeutics jumps as CASGEVY revenue ramp draws renewed buying after Q1 update — May 6, 2026
CRISPR Therapeutics Schedules May 12 Conference, Reports 500+ Q1 Casgevy Starts and H2 Phase 1 Catalysts — May 6, 2026
CRISPR Therapeutics climbs as CASGEVY momentum and pediatric filing timeline refocus buyers — Apr 30, 2026
CRISPR Therapeutics sinks as upsized $550M convertible notes stoke dilution fears — Apr 25, 2026
CRISPR Therapeutics drops 3% as biotech risk-off meets post-convert dilution worries — Apr 24, 2026

CRSP Analyst Consensus

14 analysts cover CRSP: 0 strong buy, 10 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $75.00.

Common questions about CRSP

Who is trading CRSP stock inside the company?: Recent CRSP insider activity includes KASINGER JAMES R. sold 3.18K, Kulkarni Samarth sold 10.02K, Prasad Raju sold 3.71K, Patel Naimish sold 3.15K, and Prasad Raju sold 5.85K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CRSP?: Yes. Rallies tracks CRSP insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CRSP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CRSP. It does not provide personalized investment advice.